1. Cyclodextrin- and dendrimer-conjugated graphene oxide as a nanocarrier for the delivery of selected chemotherapeutic and photosensitizing agents.
- Author
-
Siriviriyanun A, Tsai YJ, Voon SH, Kiew SF, Imae T, Kiew LV, Looi CY, Wong WF, Lee HB, and Chung LY
- Subjects
- Antineoplastic Agents metabolism, Antineoplastic Agents pharmacology, Camptothecin chemistry, Camptothecin metabolism, Camptothecin pharmacology, Cell Line, Tumor, Cell Survival drug effects, Doxorubicin chemistry, Doxorubicin metabolism, Doxorubicin pharmacology, Drug Liberation, Humans, Light, Microscopy, Atomic Force, Oxides chemistry, Photosensitizing Agents metabolism, Photosensitizing Agents pharmacology, Protoporphyrins chemistry, Protoporphyrins metabolism, Protoporphyrins pharmacology, Antineoplastic Agents chemistry, Cyclodextrins chemistry, Dendrimers chemistry, Drug Carriers chemistry, Graphite chemistry, Photosensitizing Agents chemistry
- Abstract
In this study, nanohybrid materials consisting of graphene oxide (GO), β‑cyclodextrin (CD) and poly(amido amine) dendrimer (DEN) were successfully prepared by covalent bonding. GO-CD and GO-CD-DEN were found to be potential nanocarriers for anticancer drugs including chemotherapeutics (doxorubicin (DOX), camptothecin (CPT)) and photosensitizer (protoporphyrin IX (PpIX)). GO-CD possessed 1.2 times higher DOX-loading capacity than GO due to inclusion of additional DOX to the CD. The drug loading on GO-CD-DEN increased in the order: DOX < PpIX < CPT. Enhanced cytotoxicity of DOX and CPT and also the photocytotoxicity of PpIX were observed when the drugs were loaded in GO-CD and GO-CD-DEN. Functionalization of GO with CD and CD-DEN increased the uptake in cancer cells, and both GO-CD and GO-CD-DEN nanohybrids remained in the cytoplasm and were not uptaken into the nucleus, as shown in the flow cytometry and high-content screening study., (Copyright © 2018 Elsevier B.V. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF